New Drug ApprovalNICE Recommends Givinostat for Ambulant DMD Patients Aged 6+ via NHS Innova... NICE Recommends Givinostat for Ambulant DMD Patients Aged 6+ via NHS Innova... Read Post »
New Drug ApprovalMHRA Authorizes Dawnzera for Patients With Hereditary Angioedema MHRA Authorizes Dawnzera for Patients With Hereditary Angioedema Read Post »
ResearchJohnson & Johnson Pushes for Full Depression Recovery Through Generatio... Johnson & Johnson Pushes for Full Depression Recovery Through Generatio... Read Post »
Clinical TrialsFDA Clears NRX-101 Study in Treatment-Resistant Depression and Suicidality FDA Clears NRX-101 Study in Treatment-Resistant Depression and Suicidality Read Post »
Clinical TrialsEntrada Strengthens Its Duchenne Pipeline With Positive ENTR-601-44 Study R... Entrada Strengthens Its Duchenne Pipeline With Positive ENTR-601-44 Study R... Read Post »
Clinical TrialsIncyte Shows Durable 24-Week Response With Opzelura in Moderate AD Incyte Shows Durable 24-Week Response With Opzelura in Moderate AD Read Post »
Clinical TrialsMirum Plans NDA Submission After Positive Volixibat PSC Results Mirum Plans NDA Submission After Positive Volixibat PSC Results Read Post »
ResearchNeurocrine Builds a New Roadmap for Physiologic Steroid Dosing in CAH Neurocrine Builds a New Roadmap for Physiologic Steroid Dosing in CAH Read Post »
ResearchNeurocrine Exposes the Silent Workplace Impact of Tardive Dyskinesia Neurocrine Exposes the Silent Workplace Impact of Tardive Dyskinesia Read Post »
Clinical TrialsJohnson & Johnson Breaks a Two-Decade Silence in Perianal Crohn’s Dis... Johnson & Johnson Breaks a Two-Decade Silence in Perianal Crohn’s Dis... Read Post »
New Drug ApprovalBridgeBio Gains ANVISA Clearance in Brazil for BEYONTTRA in ATTR-CM BridgeBio Gains ANVISA Clearance in Brazil for BEYONTTRA in ATTR-CM Read Post »
Clinical TrialsAbbVie Sharpens Its IBD Edge With Real-World SKYRIZI and RINVOQ Results AbbVie Sharpens Its IBD Edge With Real-World SKYRIZI and RINVOQ Results Read Post »
Clinical TrialsCytokinetics Shifts the Hypertrophic Landscape: Aficamten Scores in ACACIA ... Cytokinetics Shifts the Hypertrophic Landscape: Aficamten Scores in ACACIA ... Read Post »
Clinical TrialsViridian Therapeutics Tightens Grip on TED Pipeline With REVEAL-2 Milestone Viridian Therapeutics Tightens Grip on TED Pipeline With REVEAL-2 Milestone Read Post »
Clinical TrialsOncolytics Biotech Reports Strong Early Data for Pelareorep in mCRC Oncolytics Biotech Reports Strong Early Data for Pelareorep in mCRC Read Post »
Clinical TrialsLilly Drives Long-Term Stability in UC with Omvoh LUCENT-3 Findings Lilly Drives Long-Term Stability in UC with Omvoh LUCENT-3 Findings Read Post »
Clinical TrialsJohnson & Johnson Doubles Down on IBD Inflammation with Dual-Target The... Johnson & Johnson Doubles Down on IBD Inflammation with Dual-Target The... Read Post »
Clinical TrialsRegeneron and Sanofi Confirm Dupixent Benefits in Eosinophilic Esophagitis Regeneron and Sanofi Confirm Dupixent Benefits in Eosinophilic Esophagitis Read Post »
New Drug ApprovalASCENIV Approved for Expanded Pediatric Use in Primary Immunodeficiency ASCENIV Approved for Expanded Pediatric Use in Primary Immunodeficiency Read Post »
Clinical TrialsNetwork Analysis Shows CAPLYTA Favored in Adjunctive MDD Treatment Network Analysis Shows CAPLYTA Favored in Adjunctive MDD Treatment Read Post »
Clinical TrialsTakeda’s TAK-881 delivers comparable results to HYQVIA in PID Takeda’s TAK-881 delivers comparable results to HYQVIA in PID Read Post »
Clinical TrialsNanoViricides, Inc. Secures FDA Orphan Designation for NV-387 Measles Thera... NanoViricides, Inc. Secures FDA Orphan Designation for NV-387 Measles Thera... Read Post »
Clinical TrialsBioMarin Highlights VOXZOGO’s Long-Term Benefits on Bone and Growth BioMarin Highlights VOXZOGO’s Long-Term Benefits on Bone and Growth Read Post »
Clinical TrialsAlector Discontinues PROGRESS-AD Trial of Nivisnebart After Futility Analys... Alector Discontinues PROGRESS-AD Trial of Nivisnebart After Futility Analys... Read Post »
New Drug ApprovalFDA Clears VEPPANU, First PROTAC Therapy, for Advanced Breast Cancer FDA Clears VEPPANU, First PROTAC Therapy, for Advanced Breast Cancer Read Post »
New Drug ApprovalMHRA Clears Linerixibat (Lynavoy) for PBC-Related Itch in Adults MHRA Clears Linerixibat (Lynavoy) for PBC-Related Itch in Adults Read Post »
New Drug ApprovalJohnson & Johnson Secures FDA Nod for STELARA in Pediatric Crohn’s Johnson & Johnson Secures FDA Nod for STELARA in Pediatric Crohn’s Read Post »
Drugs Safety AlertMHRA Sets 5-Day Limit on OTC Nasal Decongestant Sprays MHRA Sets 5-Day Limit on OTC Nasal Decongestant Sprays Read Post »
New Drug ApprovalRhythm Wins EU Approval for IMCIVREE in Acquired Hypothalamic Obesity Rhythm Wins EU Approval for IMCIVREE in Acquired Hypothalamic Obesity Read Post »
New Drug ApprovalArrowhead Breaks the Triglyceride Barrier with REDEMPLO Approval in Austral... Arrowhead Breaks the Triglyceride Barrier with REDEMPLO Approval in Austral... Read Post »
Clinical TrialsCorcept Drives Survival Gain in ALS Despite Missing Primary Endpoint Corcept Drives Survival Gain in ALS Despite Missing Primary Endpoint Read Post »
New Drug ApprovalAxsome Wins FDA Decision for Auvelity in Alzheimer’s Agitation Axsome Wins FDA Decision for Auvelity in Alzheimer’s Agitation Read Post »
New Drug ApprovalNorgine Pushes the Frontier of WHIM Treatment With XOLREMDI EU Approval Norgine Pushes the Frontier of WHIM Treatment With XOLREMDI EU Approval Read Post »
Clinical TrialsTelix Advances TLX597-Tx with Positive Phase 2 Dosimetry Findings Telix Advances TLX597-Tx with Positive Phase 2 Dosimetry Findings Read Post »
New Drug ApprovalMitsubishi Tanabe Brings Steady Control to Parkinson’s with EU Nod for On... Mitsubishi Tanabe Brings Steady Control to Parkinson’s with EU Nod for On... Read Post »
Clinical TrialsNovo Nordisk Strikes at the Core of Haemophilia A with Denecimig Breakthrou... Novo Nordisk Strikes at the Core of Haemophilia A with Denecimig Breakthrou... Read Post »
Clinical TrialsNewron Hits a Regulatory Speed Bump as FDA Pauses U.S. Enrollment in ENIGMA... Newron Hits a Regulatory Speed Bump as FDA Pauses U.S. Enrollment in ENIGMA... Read Post »
Clinical TrialsVeradermics Meets Endpoints with Oral VDPHL01 in Pattern Hair Loss Study Veradermics Meets Endpoints with Oral VDPHL01 in Pattern Hair Loss Study Read Post »
Clinical TrialsGilead Leverages Priority Review to Advance Bic/Len in HIV Care Gilead Leverages Priority Review to Advance Bic/Len in HIV Care Read Post »
Clinical TrialsPfizer Sets a New Pace in Multiple Myeloma Treatment with ELREXFIO Pfizer Sets a New Pace in Multiple Myeloma Treatment with ELREXFIO Read Post »
Clinical TrialsImmunome Reports Strong Phase 3 Data, Submits NDA for Varegacestat Immunome Reports Strong Phase 3 Data, Submits NDA for Varegacestat Read Post »
Clinical TrialsFDA Real-Time Trials: AstraZeneca and Amgen Lead Breakthrough FDA Real-Time Trials: AstraZeneca and Amgen Lead Breakthrough Read Post »
New Drug ApprovalAstraZeneca’s Triple-combination inhaler Breztri approved by FDA for asth... AstraZeneca’s Triple-combination inhaler Breztri approved by FDA for asth... Read Post »
Clinical TrialsBoehringer’s survodutide Achieves Up to 16.6% Weight Loss in Phase II... Boehringer’s survodutide Achieves Up to 16.6% Weight Loss in Phase II... Read Post »
Clinical TrialsAbbVie Files Upadacitinib for FDA Approval in Alopecia Areata AbbVie Files Upadacitinib for FDA Approval in Alopecia Areata Read Post »
Clinical TrialsMundipharma Positions REZZAYO as a Steady Shield in Fungal Prevention Study Mundipharma Positions REZZAYO as a Steady Shield in Fungal Prevention Study Read Post »
Clinical TrialsOruka Therapeutics Reports Strong 16-Week Results for ORKA-001 in Psoriasis Oruka Therapeutics Reports Strong 16-Week Results for ORKA-001 in Psoriasis Read Post »
New Drug ApprovalNovartis Targets the Root of CSU With EU Approval of Rhapsido Novartis Targets the Root of CSU With EU Approval of Rhapsido Read Post »
Clinical TrialsIntellia Backs Lonvo-z as One-Time CRISPR Therapy for HAE in Phase 3 HAELO Intellia Backs Lonvo-z as One-Time CRISPR Therapy for HAE in Phase 3 HAELO Read Post »
New Drug ApprovalJohnson & Johnson Gains FDA Nod for CAPLYTA in Schizophrenia Johnson & Johnson Gains FDA Nod for CAPLYTA in Schizophrenia Read Post »
